-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Hh4vmEwH6UYoz41tyq6Rniqp/rupZ7E/XtJfV3QMlFyAaJz+5KSucEtbZRnb6U1t 7E5/iCwHSQP4fSKJ7ldDIA== 0000950123-09-014373.txt : 20090803 0000950123-09-014373.hdr.sgml : 20090801 20090616165434 ACCESSION NUMBER: 0000950123-09-014373 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 CORRESP 1 filename1.htm CORRESP
Pfizer Inc.
235 East 42nd Street
New York, New York 10017
June 16, 2009
Via EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Michael Rosenthall
  Re: Pfizer Inc.
Amendment No. 3 to Registration Statement on Form S-4
Filed June 10, 2009
File No. 333-158237
Dear Mr. Rosenthall:
     Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Pfizer Inc. (“Pfizer”) hereby requests acceleration of effectiveness of its Registration Statement on Form S-4/A (File No. 333-158237) to 4:30pm EDT on Wednesday, June 17, 2009, or as soon as possible thereafter.
     In connection with the foregoing request for acceleration of effectiveness, Pfizer hereby acknowledges the following:
•   Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•   The action of the Commission or staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve Pfizer from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•   Pfizer may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 

     Please contact Dennis J. Block, Cadwalader, Wickersham & Taft LLP at (212) 504-5555 with any questions you may have concerning this request. In addition, please notify Mr. Block when this request for acceleration has been granted.
         
  Pfizer Inc.
 		  
  /s/ David Reid  
  Name:   David Reid  
  Title:   Assistant Secretary  
 

-2-

-----END PRIVACY-ENHANCED MESSAGE-----